Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial

EClinicalMedicine(2023)10.1016/j.eclinm.2023.101889Source: DataRank Database

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial is a research paper published in EClinicalMedicine (2023). On theSindex it has a DataRank of 0.787. It has been cited 35 times, with 20 citing works in its 1-hop citation network.

N/A

0.787DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access35 citations · 20 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04488081

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 5.81)OA: goldTopics (13)Linked Datasets (4)DataCite Reuse (4)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 68%Citation Network 32%

Base Score Contribution

0.538

From this paper's citation signal

Citation Network Contribution

0.249

From 13 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 20 citers.

Exploring a patient-specific in vitro pipeline for stratification and drug response prediction of microglia-based therapeutics
Scientific Reports20254 citations24 referencesContributes 0.067
The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients
iScience20233 citations35 referencesContributes 0.040
Identifying COVID‐19 subtypes by single‐sample gene set enrichemnt analysis and providing guidance for sensitive drug selection
Journal of Medical Virology20243 citations39 referencesContributes 0.036
Multicenter randomized trial assessing efficacy and safety of aerosolized dornase Alfa in COVID-19 ARDS
Scientific Reports20253 citations57 referencesContributes 0.024
Atypical Chemokine Receptor 1 (Ackr1) -deficient Mice Resist Lethal SARS-CoV-2 Challenge
bioRxiv (Cold Spring Harbor Laboratory)20232 citations48 referencesContributes 0.023

Authors (91)

Neil R. Aggarwal ORCID,Timothy E. Albertson ORCID,Sara C. Auld ORCID,Jeremy R. Beitler ORCID,Paul Berger

Live enrichment

PubMed:36883141 PMC:PMC9981330 OpenAlex:https://openalex.org/W4322806562

NHLBI NIH HHS

Grant: P01 HL154998

NHLBI NIH HHS

Grant: R01 HL149883

NHLBI NIH HHS

Grant: R01 HL153122

NHLBI NIH HHS

Grant: R01 HL168102

Amgen Inc

Allergan US

Pfizer Inc

Takeda Pharmaceutical Company Limited

FWCI

5.81

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.eclinm.2023.101889

publisherhttps://doi.org/10.1016/j.eclinm.2023.101889

publisherhttps://api.elsevier.com/content/article/PII:S2589537023000664?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2589537023000664?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/36883141

Fields of Study

COVID-19 Clinical Research StudiesPharmacological Receptor Mechanisms and EffectsPhosphodiesterase function and regulation

Keywords

MedicineRegimenRandomized controlled trialDexamethasoneInterim analysisInternal medicineRespiratory insufficiencyAcute Lung InjuryClinical TrialSars-cov-2

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 1 of Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

10.6084/m9.figshare.26683933.v1figshare

Additional file 1 of Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

10.6084/m9.figshare.26683933figshare

Additional file 2 of Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

10.6084/m9.figshare.26683936.v1figshare

Additional file 2 of Novel subtypes of severe COVID-19 respiratory failure based on biological heterogeneity: a secondary analysis of a randomized controlled trial

10.6084/m9.figshare.26683936figshare